New Findings Reveal RNS60 Accelerates Discharge for Stroke Patients, Enhancing Recovery Times
In a groundbreaking development, Revalesio has presented compelling new data from its Phase 2 RESCUE clinical trial, showcasing how its investigational treatment, RNS60, substantially benefits patients who have suffered an acute ischemic stroke. The trial revealed that patients treated with RNS60, alongside standard endovascular thrombectomy (EVT), were discharged from the hospital an average of 4.8 days sooner compared to those who solely received EVT. This significant reduction in hospital stay was evidenced by statistical data (p=0.022), which highlights RNS60's potential for improving patient outcomes.
The RESCUE trial, which involved 82 participants, illustrated RNS60's efficacy not only in accelerating discharge times but also in minimizing brain tissue loss post-procedure. Patients administered with RNS60 experienced over a 50% reduction in infarct volume growth (p<0.05), demonstrating its cytoprotective qualities. These compelling results were presented at the American Academy of Neurology's 2025 Annual Meeting in San Diego, CA, where experts acknowledged the innovation presented in the study design.
Bert van den Bergh, Executive Chairman of Revalesio, noted the importance of such findings in the context of rising healthcare costs, emphasizing RNS60's potential to alleviate both the burden on patients and the healthcare system. By decreasing hospital stays and long-term healthcare needs, RNS60 not only enhances individual recovery experiences but also could lead to significant cost savings.
Hailing the critical insights from the trial was Dr. David S. Liebeskind from UCLA, who praised the focus on infarct growth measurement as a marker for evaluating cytoprotective drugs. According to Dr. Liebeskind, this methodology is essential for confirming treatment efficacy through reliable imaging techniques.
The oral presentation highlighted several key statistical results, pointing to the impressive functionality of RNS60: patients treated with the high dose of RNS60 demonstrated a significant lower infarct growth (50%) and increased independence (72% vs. 37% for placebo) at 90 days. Moreover, 55% of participants discharged after receiving RNS60 returned home, contrasting sharply with just 21% in the placebo group.
Greg Archambeau, Revalesio's President, reiterated the decade of research leading to RNS60’s development, commending the consistency in results observed across preclinical models, which indicated a 50% reduction in brain loss. Archambeau expressed readiness to scale up manufacturing in anticipation of potential FDA approval, highlighting the urgency of making this innovative treatment available to patients who need it.
The RESCUE clinical trial represents a pivotal moment in stroke treatment innovation. Participants underwent a carefully managed regimen where they received either a high or low dose of RNS60 or a placebo, starting before the EVT and continuing support for 48 hours. The trial's dual endpoints assessing safety and mortality highlight its comprehensive approach, while secondary endpoints provided deeper insights into disability metrics.
For more information about RNS60 and its implications for stroke recovery, visit Revalesio's website or follow their updates on LinkedIn. As stakeholders in healthcare rally towards improving outcomes while being mindful of costs, RNS60 stands poised at the forefront of a new era in neurological treatment.
The RESCUE trial, which involved 82 participants, illustrated RNS60's efficacy not only in accelerating discharge times but also in minimizing brain tissue loss post-procedure. Patients administered with RNS60 experienced over a 50% reduction in infarct volume growth (p<0.05), demonstrating its cytoprotective qualities. These compelling results were presented at the American Academy of Neurology's 2025 Annual Meeting in San Diego, CA, where experts acknowledged the innovation presented in the study design.
Bert van den Bergh, Executive Chairman of Revalesio, noted the importance of such findings in the context of rising healthcare costs, emphasizing RNS60's potential to alleviate both the burden on patients and the healthcare system. By decreasing hospital stays and long-term healthcare needs, RNS60 not only enhances individual recovery experiences but also could lead to significant cost savings.
Hailing the critical insights from the trial was Dr. David S. Liebeskind from UCLA, who praised the focus on infarct growth measurement as a marker for evaluating cytoprotective drugs. According to Dr. Liebeskind, this methodology is essential for confirming treatment efficacy through reliable imaging techniques.
The oral presentation highlighted several key statistical results, pointing to the impressive functionality of RNS60: patients treated with the high dose of RNS60 demonstrated a significant lower infarct growth (50%) and increased independence (72% vs. 37% for placebo) at 90 days. Moreover, 55% of participants discharged after receiving RNS60 returned home, contrasting sharply with just 21% in the placebo group.
Greg Archambeau, Revalesio's President, reiterated the decade of research leading to RNS60’s development, commending the consistency in results observed across preclinical models, which indicated a 50% reduction in brain loss. Archambeau expressed readiness to scale up manufacturing in anticipation of potential FDA approval, highlighting the urgency of making this innovative treatment available to patients who need it.
The RESCUE clinical trial represents a pivotal moment in stroke treatment innovation. Participants underwent a carefully managed regimen where they received either a high or low dose of RNS60 or a placebo, starting before the EVT and continuing support for 48 hours. The trial's dual endpoints assessing safety and mortality highlight its comprehensive approach, while secondary endpoints provided deeper insights into disability metrics.
For more information about RNS60 and its implications for stroke recovery, visit Revalesio's website or follow their updates on LinkedIn. As stakeholders in healthcare rally towards improving outcomes while being mindful of costs, RNS60 stands poised at the forefront of a new era in neurological treatment.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.